PERSISTA BIO INC

Founded 2023 · CIK 0002131619 · Medtech · Private

Oxygenated cell encapsulation device (O2Line™ implant system) for encapsulating insulin-producing cells to treat Type 1 diabetes

Grants
$1.4M
2 awards
Sector median: 1
Raised
—
1 Form D · Apr 2026
5 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · Advanced Pre-Clinical Development of O2LineTM System for Type 1 Diabetes Cell Therapy$1,093,967
Federal grantDepartment of Health and Human Services · Phase I · Manufacturing Clinical-Grade Cell Capsule of O2Line(TM) Implant System for T1D$287,250
Federal grant · SBIR/STTRForm D · SEC

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1664BARATI MEDICAL, LLC——
1665IMAGEAID, INC.—$200K
1666Vesica Health, Inc.—$4.5M
1667PERSISTA BIO INC—
1668Wisdom.io Inc.—$50K
1669CELLECTGEN, INC.——
1670ALTRUMED LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 1 related persons
  • Linda TempelmanDirector · Executive Officer

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.